11,106 reports of this reaction
7.3% of all PEMBROLIZUMAB reports
#1 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #1 most commonly reported adverse reaction for PEMBROLIZUMAB, manufactured by Merck Sharp & Dohme LLC. There are 11,106 FDA adverse event reports linking PEMBROLIZUMAB to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 7.3% of all 152,954 adverse event reports for this drug.
PEMBROLIZUMAB has an overall safety score of 88 out of 100. Patients taking PEMBROLIZUMAB who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is moderately reported among PEMBROLIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for PEMBROLIZUMAB:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 11,106 FDA reports for PEMBROLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 7.3% of all adverse event reports for PEMBROLIZUMAB, making it one of the most commonly reported side effect.
If you experience malignant neoplasm progression while taking PEMBROLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.